WHO-Recommended "Six-Month Fluoroquinolone-Containing Regimen" Shows Efficacy in South Korea
Seoul St. Mary's Hospital team analyzes 99 patients with isoniazid-monoresistant pulmonary tuberculosis
Fluoroquinolone-containing regimen shows similar treatment outcomes and safety to regimen without fluoroquinolones
Prospective multicenter cohort study involving 15 hospitals
Seoul St. Mary's Hospital said a research team led by Professor Min Jinsu of its Division of Pulmonary Medicine found no significant difference in treatment outcomes or safety between a six-month regimen containing a fluoroquinolone antibiotic, as recommended by the World Health Organization (WHO), and a regimen without a fluoroquinolone in patients with isoniazid-monoresistant pulmonary tuberculosis.
According to Seoul St. Mary's Hospital on October 28, the study was conducted as a prospective multicenter cohort study involving 15 hospitals in South Korea. It evaluated the WHO-recommended regimen in real-world clinical practice.
From left: Min Jinsoo and Lee Jongmin, professors in the Division of Pulmonary Medicine at Seoul St. Mary's Hospital. Seoul St. Mary's Hospital
View original imageWHO recommends a six-month regimen for isoniazid-monoresistant tuberculosis that combines rifampicin, ethambutol and pyrazinamide with a fluoroquinolone antibiotic, either levofloxacin or moxifloxacin. However, prospective evidence evaluating the efficacy and safety of this regimen in real-world clinical practice has been limited.
Isoniazid is a key drug used with rifampicin in the standard first-line treatment for tuberculosis. When resistance to isoniazid develops, the standard treatment strategy must be adjusted. Isoniazid-monoresistant tuberculosis is distinct from multidrug-resistant tuberculosis, but selecting an appropriate treatment regimen is important.
The research team followed 2,871 adults with pulmonary tuberculosis at 15 hospitals participating in the Public-Private Mix national tuberculosis control project from 2016 to 2024. Of these, 99 patients whose drug-susceptibility tests showed resistance to isoniazid alone were included in the comparison of treatment outcomes and safety.
Of the total patients, 55 (55.6%) received a regimen that added a fluoroquinolone antibiotic to rifampicin, ethambutol and pyrazinamide. The remaining 44 (44.4%) received a regimen without a fluoroquinolone antibiotic.
The analysis found that the proportion of patients who did not experience a recurrence within 12 months after completing treatment was 70.9% in the fluoroquinolone-containing regimen group and 72.7% in the group that did not receive a fluoroquinolone. The difference between the two groups was not statistically significant, and the same result was found after adjusting for multiple variables. Severe adverse events occurred in 25.3% of all patients. They occurred in 29.1% of the fluoroquinolone-containing regimen group and 20.5% of the group that did not receive a fluoroquinolone, but the difference between the two groups was not statistically significant.
The study provides prospective evidence that the WHO-recommended six-month regimen achieves treatment outcomes similar to those of existing alternative regimens in real-world clinical practice in South Korea. However, because this was an observational study in which treatment regimens were not randomly assigned and the analysis was limited to 99 patients, further research is needed before the findings can be generalized.
Hot Picks Today
"Two Spend 500,000 Won in a Flash, Yet Wait Two Hours?" ... 'Dreamland' Shunned by Kids and Foreign Tourists
- The Era of Getting 200 Million Won After 30 Years Is Over... A Japanese Bank's "Perpetual Department Head" Who Just Clocked In Cries Out
- Spain Hit by Its Worst Tragedy... Lee Kangin, Moreno and Real Madrid Join Soccer World in Mourning
- They Said, “Make It Your Home for Life” - Then Suddenly Kicked 200 Passengers Off... What Happened to the Around-the-World Cruise?
- "130 Rice Bowls Sold Out in a Day"... 'Unfiltered Face' Adds 8 Million Won to Night Market Sales: China's Bungeunwoo
"Isoniazid-monoresistant pulmonary tuberculosis is the most common form of drug-resistant tuberculosis, but evidence on its treatment in real-world clinical practice has been limited," Professor Min Jinsu said. "This study confirmed that the WHO-recommended six-month regimen can be applied effectively and safely to patients in South Korea as well. It should help clinicians choose an appropriate regimen by taking into account each patient's characteristics and adverse drug reactions." The findings were published in the European Journal of Clinical Microbiology & Infectious Diseases.
© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.